GlobeNewswire EN Nachrichten

 

ROCKVILLE, Md. and SUZHOU, China, April 19, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it will present four preclinical studies in poster format at the American Association for Cancer Research (AACR) 2026 Annual Meeting, held April 17 to 22, 2026 in San Diego, CA, USA....

STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs...

WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, announced new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) showing greater neurologic benefit versus standard of care (SoC) in Wilson disease patients with neurologic symptoms at baseline. The data will be presented today at the American Academy of Neurology (AAN) Annual Meeting 2026, taking place April 18-22, 2026....

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma...

VANCOUVER, British Columbia and BOSTON, MA, April 19, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today presented positive data from the Phase 3 X-TOLE2 study highlighting the efficacy and safety of azetukalner in focal onset seizures (FOS) at the American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois. Xenon is also presenting data at the AAN meeting that reinforce the significant opportunity for azetukalner in epilepsy, including 48-month data from the ongoing X-TOLE open-label extension (OLE) study, as well as real-world data reinforcing the potential value that no-titration options like azetukalner would bring to epilepsy management. Azetukalner (AZK) is a novel, potent, KV7 potassium channel opener currently in clinical development for epilepsy and depression....

Míla Holding hf.: Confirmation of the report on the financial obligations of MILA 300929 bond...

Company announcement – No. 8 / 2026...

Company announcement – No. 7 / 2026...

REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) clinical data for zoldonrasib, an oral RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC). Results were highlighted in the official press program at the American Association for Cancer Research (AACR) Annual Meeting and will be featured in a plenary oral presentation today, April 19, 2026, at 1:30 p.m. PDT....

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass, April 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the presentation of new preclinical data across three posters at the American Association for Cancer Research (AACR) Annual Meeting 2026....

Schneider Electric announces its participation and activities at Hannover Messe 2026...

Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months ...

iCAUR V27 secures L3 off-road cert, proving robust new energy off-road capability....

ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study...

April 18, 2026, 7:00 AM CEST...

VANCOUVER, British Columbia, April 17, 2026 (GLOBE NEWSWIRE) -- B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) (“B2Gold” or the “Company”) announced today that a fire occurred in certain areas of the crushing circuit at the Goose Mine in the evening on April 16, 2026. On-site emergency responders were deployed and immediately initiated response procedures, and the fire was fully extinguished. No injuries were reported, no medical treatment was required, and mining operations are continuing on plan. The Company has been in contact with the relevant regulatory authorities....

Ordinary shares will continue to trade on the Nasdaq Capital Market, and the Company's listing on such exchange is not affected by the receipt of the Notice Ordinary shares will continue to trade on the Nasdaq Capital Market, and the Company's listing on such exchange is not affected by the receipt of the Notice...

GUADALAJARA, Mexico, April 17, 2026 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) today announced the filing of its annual report, corresponding to the year ended December 31, 2025, to the Mexican National Banking and Securities Commission (“CNBV”), the Mexican Stock Exchange (“BMV”), and the Institutional Stock Market Exchange (“BIVA”), as well as the filling of its Form 20-F to the U.S. Securities and Exchange Commission (“the SEC”)....

VANCOUVER, British Columbia, April 17, 2026 (GLOBE NEWSWIRE) -- Ibero Mining Corp. (TSX.V:IMC) (OTCQB:AUCCF) (“Ibero” or the “Company”) is pleased to announce that, further to its news releases dated February 12, 2026 and March 30, 2026, and further to the partial revocation order granted by the British Columbia Securities Commission (“BCSC”) on February 11, 2026, and variation orders granted by the BCSC on February 11, 2026, March 19, 2026 and March 27, 2026 (collectively, the “Partial Revocation Order”), it has closed the non-brokered private placement by the issuance of 16,666,667 units in the capital of the Company (“Units”) at a price of $0.03 per Unit for aggregate gross proceeds of $500,000. Each Unit consists of one common share of the Company (“Common Share”) and one common share purchase warrant entitling the holder to purchase one Common Share at an exercise price of $0.08 for a period of thirty-six months from the closing date (the “Private Placement”)....

RANCHO CORDOVA, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Five Star Bancorp (Nasdaq: FSBC) (“Five Star” or the “Company”), a holding company that operates through its wholly owned banking subsidiary, Five Star Bank (the "Bank"), announced today the declaration of a cash dividend of $0.25 per share on the Company's voting common stock. The dividend is expected to be paid on May 11, 2026, to shareholders of record as of May 4, 2026....